Relationship between complete pathologic response to neoadjuvant chemotherapy and survival in triple-negative breast cancer

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 26-33

  Hatzis, Christos ^a   Symmans, W Fraser ^b   Zhang, Ya ^b   Gould, Rebekah E ^b   Moulder, Stacy L ^b   Hunt, Kelly K ^b   Abu Khalaf, Maysa ^a   Hofstatter, Erin W ^a   Lannin, Donald ^a   Chagpar, Anees B ^a   Pusztai, Lajos ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BOOTSTRAPPING; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; PATHOLOGIC COMPLETE RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; ADULT; AGED; CANCER STAGING; FEMALE; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; ODDS RATIO; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84954319471     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3304     Document Type: Article

References (28)

1. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clinical Oncol 1999;17:460-9.
2. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clinical Oncol 2008;26:778-85.
3. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clinical Oncol 2012;30:1796-804.
4. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
5. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Annal Oncol 2007;18:874-80.
6. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clinical Oncol 2007;25:4414-22.
7. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clinical Oncol 2005;23:5983-92.
8. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71.
9. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neo adjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clinical Oncol 2005; 23:3676-85.
10. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
11. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neo adjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neo adjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010;375:377-84.
12. ASCO. FDA Approves Pertuzumab for Neo adjuvant Breast Cancer. 2013 [cited 2013 Oct 1]. Available from: Eww.asco.org/advocacy/fda-approvespertuzumab-neoadjuvant-breast-cancer.
13. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012;366:2438-41.
14. Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, et al. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): An open-label, 2-2 factorial randomised phase 3 trial. Lancet Oncol 2014;15:201-12.
15. von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014;15:747-56.
16. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 2014;384:164-72.
17. Piccart-Gebhart M, Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T!L), or their combination (TL) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clinical Oncol 2014;32:suppl; abstr LBA4.
18. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (Neo ALTTO): A randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633-40.
19. Symmans WF, Wei C, Gould R, Zhang Y, Hunt KK, Buchholz TA, et al. Longterm prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy. Cancer Res 2013;73:S6.
20. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.
21. Efron B. Censored data and the bootstrap. J Am Stat Assoc 1981;76:312-9.
22. Akritas MG. Bootstrapping the Kaplan-Meier estimator. J Am Stat Assoc 1986;81:1032-8.
23. Bender R, Augustin T, Blettner M. Generating survival times to simulate Cox proportional hazards models. Stat Med 2005;24:1713-23.
24. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.
25. Iwamoto T, Lee JS, Bianchini G, Hubbard RE, Young E, Matsuoka J, et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 2011;130:155-64.
26. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clinical Oncol 2010; 28:105-13.
27. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J Clinical Oncol 2013;31:860-7.
28. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007;13:2061-2067.